<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04957914</url>
  </required_header>
  <id_info>
    <org_study_id>16936</org_study_id>
    <secondary_id>I8H-MC-BDCI</secondary_id>
    <secondary_id>2019-003537-42</secondary_id>
    <nct_id>NCT04957914</nct_id>
  </id_info>
  <brief_title>A Multiple-Dose Study of LY3209590 in Participants With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Effects of LY3209590 on Frequency and Severity of Hypoglycaemia Under Conditions of Increased Hypoglycaemic Risk Compared to Insulin Glargine in Participants With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the effect of study drug known as LY3209590&#xD;
      compared to insulin glargine administered in participants with type 2 diabetes mellitus&#xD;
      (T2DM). Side effects and tolerability will be documented. The study will last almost six&#xD;
      months and 21 visits for each participant including screening period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 14, 2021</start_date>
  <completion_date type="Anticipated">July 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Documented Hypoglycemia</measure>
    <time_frame>Baseline through Day 186</time_frame>
    <description>Incidence of Documented Hypoglycemia</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Insulin Glargine (Period 1)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin glargine administered subcutaneously (SC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3209590 (Period 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3209590 administered SC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Insulin Glargine (Period 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3209590</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY3209590 (Period 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have been diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 1 year prior to&#xD;
             screening&#xD;
&#xD;
          -  Body mass index (BMI) of 18.5 to 40.0 kilograms per meter squared (kg/m²)&#xD;
&#xD;
          -  Be treated for T2DM with stable dose of metformin, a stable dose of a dipeptidyl&#xD;
             peptidase-4 (DPP-4) inhibitor with or without metformin, or a stable dose of a&#xD;
             glucagon-like peptide-1 (GLP-1) receptor agonist with or without metformin for at&#xD;
             least 3 months prior to screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have an abnormality in the 12-lead ECG&#xD;
&#xD;
          -  Have a supine blood pressure at screening&#xD;
&#xD;
          -  Have alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;2.5x upper&#xD;
             limit of normal (ULN)&#xD;
&#xD;
          -  Have a history of or current cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal, endocrine (except T2DM and controlled thyroid disease),&#xD;
             haematological, or neurological disorders&#xD;
&#xD;
          -  Are receiving chronic (lasting longer than 14 consecutive days) systemic or inhaled&#xD;
             glucocorticoid therapy&#xD;
&#xD;
          -  Have an average weekly alcohol intake&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@Lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung</name>
      <address>
        <city>Neuss</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>4921314018333</phone>
    </contact>
    <investigator>
      <last_name>Grit Andersen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 8, 2021</study_first_submitted>
  <study_first_submitted_qc>July 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

